Patents by Inventor James E. Zadina
James E. Zadina has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220056075Abstract: A method for treating opioid use disorder comprises administering to a subject a pharmaceutical composition comprising a cyclic peptide of Formula I or a pharmaceutically acceptable salt thereof in a pharmaceutically acceptable carrier; wherein the peptide of formula X1-c[X2-X3-Phe-X4]-X5 is administered in place of, and as a substitute for an opioid to which the subject is addicted. X1 is Tyr or 2,6-Dmt; X2 is an acidic or basic D-amino acid; X3 is Trp or Phe; there is an amide bond between the sidechains of X2 and X4; X5 is NHR (R=H or alkyl) or an amino acid amide. When X2 is an acidic D-amino acid, X4 is a basic amino acid, X3 is Phe, and X5 is NHR; and when X2 is a basic D-amino acid, X4 is an acidic amino acid, and X3 is Trp.Type: ApplicationFiled: November 3, 2021Publication date: February 24, 2022Applicants: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND, DEPARTMENT OF VETERANS AFFAIRS (US)Inventor: James E. ZADINA
-
Patent number: 10919939Abstract: The invention relates to cyclic peptide agonists that bind to the mu (morphine) opioid receptor and their use in the treatment of acute and/or chronic pain. Embodiments of the invention are directed to cyclic analogs of endomorphin. These peptide analogs exhibit decreased tolerance relative to morphine, increased solubility compared to similar tetrapeptide analogs, while maintaining favorable or improved therapeutic ratios of analgesia to side effects.Type: GrantFiled: April 3, 2017Date of Patent: February 16, 2021Assignees: The Administrators of the Tulane Educational Fund, United States Department of Veterans AffairsInventors: James E. Zadina, Laszlo Hackler
-
Publication number: 20180222940Abstract: The invention relates to cyclic peptide agonists that bind to the mu (morphine) opioid receptor and their use in the treatment of acute and/or chronic pain. Embodiments of the invention are directed to cyclic pentapeptide and hexapeptide analogs of endomorphin that have (i) a carboxy-terminal extension with an amidated hydrophilic amino acid and (ii) a substitution in amino acid position 2. These peptide analogs exhibit decreased tolerance relative to morphine, increased solubility compared to similar tetrapeptide analogs, while maintaining favorable or improved therapeutic ratios of analgesia to side effects.Type: ApplicationFiled: September 14, 2017Publication date: August 9, 2018Applicants: The Administrators of the Tulane Educational Fund, United States Department of Veterans AffairsInventors: James E. ZADINA, Laszlo HACKLER
-
Publication number: 20170369531Abstract: The invention relates to cyclic peptide agonists that bind to the mu (morphine) opioid receptor and their use in the treatment of acute and/or chronic pain. Embodiments of the invention are directed to cyclic pentapeptide and hexapeptide analogs of endomorphin that have (i) a carboxy-terminal extension with an amidated hydrophilic amino acid and (ii) a substitution in amino acid position 2, and in some embodiments, a 2?,6?-dimethyltyrosine (Dmt) residue in place of the N-terminal tyrosine residue a position 1. These peptide analogs exhibit increased solubility compared to similar tetrapeptide analogs while maintaining favorable or improved therapeutic ratios of analgesia to side effects.Type: ApplicationFiled: March 6, 2017Publication date: December 28, 2017Applicants: The Administrators of the Tulane Educational Fund, Department of Veterans Affairs (US)Inventors: James E. ZADINA, Laszlo HACKLER
-
Publication number: 20170362276Abstract: The invention relates to cyclic peptide agonists that bind to the mu (morphine) opioid receptor and their use in the treatment of acute and/or chronic pain. Embodiments of the invention are directed to cyclic analogs of endomorphin. These peptide analogs exhibit decreased tolerance relative to morphine, increased solubility compared to similar tetrapeptide analogs, while maintaining favorable or improved therapeutic ratios of analgesia to side effects.Type: ApplicationFiled: April 3, 2017Publication date: December 21, 2017Applicants: The Administrators of the Tulane Educational Fund, United States Department of Veterans AffairsInventors: James E. ZADINA, Laszlo HACKLER
-
Publication number: 20160176930Abstract: The invention relates to cyclic peptide agonists that bind to the mu (morphine) opioid receptor and their use in the treatment of acute and/or chronic pain. Embodiments of the invention are directed to cyclic pentapeptide and hexapeptide analogs of endomorphin that have (i) a carboxy-terminal extension with an amidated amino acid and (ii) a D-amino acid substitution in position 2. These peptide analogs exhibit decreased tolerance relative to morphine, increased solubility compared to similar tetrapeptide analogs, while maintaining favorable or improved therapeutic ratios of analgesia to side effects.Type: ApplicationFiled: December 18, 2015Publication date: June 23, 2016Applicants: The Administrators of the Tulane Educational Fund, United States Department of Veterans AffairsInventors: James E. ZADINA, Laszlo HACKLER
-
Publication number: 20160009764Abstract: The invention relates to cyclic peptide agonists that bind to the mu (morphine) opioid receptor and their use in the treatment of acute and/or chronic pain. Embodiments of the invention are directed to cyclic pentapeptide and hexapeptide analogs of endomorphin that have (i) a carboxy-terminal extension with an amidated hydrophilic amino acid and (ii) a substitution in amino acid position 2, and in some embodiments, a 2?,6?-dimethyltyrosine (Dmt) residue in place of the N-terminal tyrosine residue a position 1. These peptide analogs exhibit increased solubility compared to similar tetrapeptide analogs while maintaining favorable or improved therapeutic ratios of analgesia to side effects.Type: ApplicationFiled: September 4, 2015Publication date: January 14, 2016Applicants: DEPARTMENT OF VETERANS AFFAIRS (US), THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUNDInventors: James E. ZADINA, Laszlo HACKLER
-
Patent number: 8716436Abstract: The invention relates to cyclic peptide agonists that bind to the mu (morphine) opioid receptor and their use in the treatment of acute and/or chronic pain. Embodiments of the invention are directed to cyclic pentapeptide and hexapeptide analogs of endomorphin that have (i) a carboxy-terminal extension with an amidated hydrophilic amino acid and (ii) a substitution in amino acid position 2. These peptide analogs exhibit decreased tolerance relative to morphine, increased solubility compared to similar tetrapeptide analogs, while maintaining favorable or improved therapeutic ratios of analgesia to side effects.Type: GrantFiled: May 22, 2012Date of Patent: May 6, 2014Assignees: The Administrators of the Tulane Educational Fund, U.S. Department of Veterans AffairsInventors: James E. Zadina, Laszlo Hackler
-
Publication number: 20120322740Abstract: The invention relates to cyclic peptide agonists that bind to the mu (morphine) opioid receptor and their use in the treatment of acute and/or chronic pain. Embodiments of the invention are directed to cyclic pentapeptide and hexapeptide analogs of endomorphin that have (i) a carboxy-terminal extension with an amidated hydrophilic amino acid and (ii) a substitution in amino acid position 2. These peptide analogs exhibit decreased tolerance relative to morphine, increased solubility compared to similar tetrapeptide analogs, while maintaining favorable or improved therapeutic ratios of analgesia to side effects.Type: ApplicationFiled: May 22, 2012Publication date: December 20, 2012Applicants: UNITED STATES DEPARTMENT OF VETERANS AFFAIRS, THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUNDInventors: James E. ZADINA, Laszlo HACKLER
-
Patent number: 6303578Abstract: This invention relates to certain peptides and linear and cyclic analogs thereof that bind to the mu (morphine) opiate receptor with higher affinity, selectivity and potency than currently available peptides. This invention also relates to pharmaceutical preparations containing an effective amount of the peptides or salts thereof, and methods for providing analgesia, relief from gastrointestinal disorders such as diarrhea, and therapy for drug dependence containing a pharmaceutically effective amount of the peptides.Type: GrantFiled: February 18, 1999Date of Patent: October 16, 2001Assignee: Administrators of the Tulane Educational FundInventors: James E. Zadina, Abba J. Kastin, Laszlo Hackler
-
Patent number: 5885958Abstract: This invention relates to certain peptides and linear and cyclic analogs thereof that bind to the mu (morphine) opiate receptor with higher affinity, selectivity and potency than currently available peptides. This invention also relates to pharmaceutical preparations containing an effective amount of the peptides or salts thereof, and methods for providing analgesia, relief from gastrointestinal disorders such as diarrhea, and therapy for drug dependence containing a pharmaceutically effective amount of the peptides.Type: GrantFiled: March 25, 1997Date of Patent: March 23, 1999Assignee: Administrators of the Tulane Educational FundInventors: James E. Zadina, Abba J. Kastin, Laszlo Hackler